Compare stocks

MNDR vs STTK

Mobile-health Network Solutions Class A Ordinary Shares and Shattuck Labs, Inc. Common Stock

Compare the businesses

Mobile-health Network Solutions Class A Ordinary Shares

Mobile-health Network Solutions, an investment holding company, provides telehealth solutions primarily in Singapore. The company operates in two segments: Telemedicine and Other Services and Sale of Medicine and Medical Devices. It offers MaNaDr platform, a 360-degree healthcare ecosystem, which connects users and service providers through the range of healthcare services and product offerings that can be accessed through the mobile application and website. The company also provides a suite of medical-related and other services, including teleconsultations and health check-up services, vaccinations, skin and aesthetics services, and other services. In addition, it offers healthcare and wellness products through its online e-commerce platform; wholesale distribution of pharmaceutical products to clinics; and MaNaCare, a platform that provides a range of corporate healthcare and wellness services, including GP, specialist and allied healthcare panel services, tele-consultation services, in-person clinics, on-site health screening, and online marketplace, as well as wellness programs to corporate customers. Further, the company develops IT systems on mobile phone and web portals; operates pharmacies, clinics, and drug stores; and offers beauty and other personal care services, as well as other general medical services. The company was founded in 2009 and is headquartered in Singapore.

Open MNDR dashboard ↗

Shattuck Labs, Inc. Common Stock

Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases. The company's lead product candidate includes SL-325, a DR3 blocking monoclonal antibody, which activates immune responses through binding a single receptor, DR3; and SL-425. It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inflammatory bowel disease; and a series of bispecific antibodies targeting DR3 and other clinically validated targets. In addition, the company is involved in the advancement of its lead TRIM7 inhibitors through preclinical development as future internal pipeline candidates in oncology. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

Open STTK dashboard ↗

Sign in to keep comparing stocks

You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.

3 of 3 daily views used. Your allowance resets at midnight Eastern time. Refreshes and chart changes do not use another view.

Sign in →

New to NexusTrade? Create a free account.

Choose another comparison ↗